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The aims of this study were to determine whether
Centers for Disease Control high risk (CDCHR) status
of organ donors affects kidney utilization and recipient
survival. Data from the Scientific Registry of Transplant
Recipients were used to examine utilization rates of
45 112 standard criteria donor (SCD) deceased donor
kidneys from January 1, 2005, and February 2, 2009.
Utilization rates for transplantation were compared
between CDCHR and non-CDCHR kidneys, using lo-
gistic regression to control for possible confounders.
Cox regression was used to determine whether CDCHR
status independently affected posttransplant survival
among 25 158 recipients of SCD deceased donor kid-
neys between January 1, 2005, and February 1, 2008.
CDCHR kidneys were 8.2% (95% CI 6.9–9.5) less likely to
be used for transplantation than non-CDCHR kidneys;
after adjusting for other factors, CDCHR was associ-
ated with an odds ratio of utilization of 0.67 (95% CI
0.61–0.74). After a median 2 years follow-up, recipients
of CDCHR kidneys had similar posttransplant survival
compared to recipients of non-CDCHR kidneys (hazard
ratio 1.06, 95% CI 0.89–1.26). These findings suggest
that labeling donor organs as ‘high risk’ may result in
wastage of approximately 41 otherwise standard kid-
neys per year.
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Introduction
Developed in 1994 by the Centers for Disease Control
(CDC), the Public Health Service guidelines shown in
Table 1 designate organ donors as ‘high risk’ if they meet
any of the criteria for high-risk behaviors that present an
increased chance of human immunodeficiency virus (HIV)
transmission (1). This designation is intended to alert and
protect transplant candidates from the risks of infection,
because even negative antibody testing of potential donors
does not entirely eliminate the possibility of disease trans-
mission due to the window period between infection and
seroconversion (2). Nevertheless, the actual risk of false
negative disease transmission is likely very low. Although
limited by a voluntary reporting system, current estimates
suggest the combined risk of transmission of HIV, hepatitis
B or hepatitis C from a seronegative donor is less than 1%
(3). For example, until recently a case of HIV transmission
from solid organ transplantation had not been reported in
the United States in more than 20 years (4). Furthermore,
studies have shown that utilizing nucleic acid amplification
testing during the screening process can further reduce
the risk of disease transmission, though the cost-benefit
remains uncertain.
Despite the low risk of transmission, disclosure of CDCHR
donor status and informed consent of transplant recipi-
ents is recommended by ethicists and required by Organ
Procurement and Transplantation Network (OPTN) policy
(5,6). Specific mechanisms of disclosure and informed con-
sent are left up to each transplant center, and a study on
this matter has demonstrated that significant within- and
between-center variation exists in disclosure practices (2).
We hypothesized that the CDCHR label might result in po-
tential recipients and transplant physicians turning down or-
gans that would be otherwise suitable for transplantation.
We chose to focus on the utilization of kidney allografts
because kidney transplantation is not as immediately life-
saving as transplantation of many other solid organs, and
thus risks of disease transmission may be given stronger
consideration.
Therefore, the aims of this study were (1) to determine
whether CDCHR labeling affects deceased donor kid-
ney utilization after controlling for other factors and (2)
to determine whether use of CDCHR kidneys from de-
ceased donors negatively impacts patients’ posttransplant
survival.
Methods
The data source was the Scientific Registry of Transplant Recipients (SRTR)
Standard Analysis File as of February 2, 2009. To analyze utilization rate, we
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Table 1: Public Health Service criteria for High Risk Behavior
(1, 2)
Category Description
MSM Men who have had sex with another man in
the preceding 5 years
IDU Persons who report nonmedical intravenous,
intramuscular or subcutaneous injection of
drugs in the preceding 5 years
Hemophiliac Persons with hemophilia or related clotting
disorders who have received human derived
clotting factor concentrates
Prostitution Men and women who have engaged in sex in
exchange for money or drugs in the
preceding 5 years
High-risk sex Persons who have had sex in the preceding 12
months with any person described in items
1–4 above or with a person known or
suspected to have HIV infection
Exposed to HIV Persons who have been exposed in the
preceding 12 months to known or suspected
HIV-infected blood through percutaneous
inoculation or through contact with an open
wound, non-intact skin, or mucous
membrane
Jail Inmates of correctional systems (This exclusion
is to address issues such as difficulties with
informed consent and increased prevalence
of HIV in this population.)
chose deceased kidney donors who were standard criteria other than their
behavioral risk profile, and donated between January 1, 2005, and February
2, 2009 (n = 45 128 kidneys). Standard criteria donors (SCD) from whom at
least one organ was used for the purpose of transplantation were chosen
in order to analyze kidneys that would otherwise have a reasonable chance
of being used. This particular time period was chosen to begin when the
CDCHR label started being routinely recorded in the SRTR file. To analyze
posttransplant survival, the sample consisted of individuals who underwent
deceased-donor single kidney transplantation from SCD donors during the
time period between January 1, 2005, and February 1, 2008 (n = 25 868
patients). Transplants within the last year of data (February 2, 2008, to
February 2, 2009) were excluded to allow a minimum follow-up time of 1
year. Time at-risk was censured at the last expected follow-up.
Certain variables had greater than 1% missing values. These variables were
donor creatinine (1.3% missing), cold ischemia time (11.3% missing) and
peak panel reactive antibody (peak PRA) (1.1% missing). To avoid bias as-
sociated with listwise deletion of large numbers of observations, we used
standard methods of imputation for these variables with significant missing
data (7). An imputation flag was created and included in all subsequent anal-
yses to protect against bias from the imputation process. In the case of the
cold ischemia time and peak PRA, the imputation flag demonstrated that
data was missing in a statistically significant manner. Therefore we gener-
ated a missing data variable and included it in the analysis to adjust for bias
from these potential confounders. This prevented the observations with
missing data from being excluded during further statistical analysis. Small
amounts of missing data from other variables resulted in a final sample size
of 45 112 kidneys for the multivariable utilization analysis and a sample size
of 25 858 patients for the multivariable survival analysis.
Utilization rate was defined as kidneys transplanted as a percentage of
the total available kidneys from deceased donors, with a donor defined as
anyone from whom at least one organ was recovered for the purpose of
transplantation. The proportion of available kidneys that were subsequently
transplanted was calculated for both CDCHR and non-CDCHR donors, and
the chi-square test was used to determine the statistical significance of the
difference.
Next, multivariable logistic regression was used to adjust for other donor
characteristics, which might confound utilization comparisons between CD-
CHR versus non-CDCHR organs. Variables for donor characteristics included
in the analysis were CDCHR status, donation after cardiac death, age, race,
cause of death, height, serum creatinine, gender, blood type O, HBV pos-
itive, HCV positive, history of hypertension and history of diabetes (8,9).
Donor age, race and cause of death were each stratified into several sub-
categories. Because organ utilization may have been affected by other vari-
ables not present in the database, we performed sensitivity analysis by
adjusting for number of organs transplanted per donor (OTPD). We also
analyzed utilization rates over time to determine the effect of enactment
of the OPTN policy in December 2007 requiring notification of recipients
about CDCHR status. Then, predicted probabilities were calculated to de-
termine expected utilization rates during this time period if the CDCHR label
did not exist. This method involves using the regression model to predict
utilization of all SCD kidneys at baseline and then with CDCHR set to zero,
and was used to calculate the number of otherwise usable kidneys that are
potentially ‘wasted’ per year because of the CDCHR appellation.
Finally, Cox proportional hazards regression was used to determine if trans-
plantation of CDCHR kidneys is associated with decreased posttransplant
survival after controlling for potential confounders. Variables included the
same donor characteristics from the analysis above, in addition to the fol-
lowing recipient characteristics: age, race, gender, history of diabetes, pre-
vious transplants, previous dialysis and peak PRA, as well as the following
transplant characteristics: cold ischemia time, and whether the kidney was
nationally or locally recovered (9). Death status and death date for the Cox
analysis were drawn from the Social Security Master Death File data in the
SRTR data set.
Results
Over the studied time period (January 2005–February
2009), there were 45 128 donated kidneys, of which 4482
(9.9%) were from CDCHR donors and 40 646 (90.1%) were
from non-CDCHR donors. As shown in Table 2, CDCHR
donors tended to have more characteristics associated
with favorable graft function such as young age and lower
serum creatinine. In total, 37 924 of the donated kidneys
were transplanted (utilization rate 84.1%). Of the 4482 CD-
CHR kidneys, 3437 were used for transplantation (utiliza-
tion rate 76.7%, 95% CI 75.4–77.9), while of the 40 646
non-CDCHR kidneys, 34 505 were used for transplantation
(utilization rate 84.9%, 95% CI 84.5–85.2). Thus, the uti-
lization rate of CDCHR kidneys was 8.2% (95% CI 6.9–9.5)
lower than that of non-CDCHR kidneys. When analyzed by
donor, utilization rates of both kidneys versus one kidney
were 67.4 and 9.2% for CDCHR donors, respectively, com-
pared to 70.6 and 7.5% for non-CDCHR donors (p < 0.001).
In the multivariable logistic regression shown in Table 3,
donor characteristics significantly associated with lower
utilization were older age, donation after cardiac death, His-
panic or Other, non-Caucasian race, cause of death other
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Table 2: Donor characteristics
CDC high Non-CDC
risk high risk
(n = 2241 (n = 20 323
donors) donors) p-Value
Median age (years) 34 35 0.02
Gender (% male) 71.2% 61.5% <0.001
Race
Black 18.1% 14.4% <0.001
Hispanic/Latino 12.7% 15.1% 0.003
Caucasian 67.4% 67.5% 0.93
Non-Caucasian other 1.8% 3.0% 0.001
Median height (cm) 175.3 172.7 <0.001
Cardiac death 8.6% 10.7% 0.002
Blood type O 49.3% 47.3% 0.07
HBV positive 11.3% 3.7% <0.001
HCV positive 17.2% 2.7% <0.001
History of hypertension 18.6% 18.4% 0.87
History of diabetes 5.3% 6.0% 0.18
Serum creatinine (mg/dL) 1.0 1.1 <0.001
Cause of death
Anoxia 28.3% 19.7% <0.001
Cerebrovascular accident 23.1% 28.9% <0.001
Head trauma 45.3% 46.5% 0.05
Other 3.2% 3.9% 0.12
than head trauma, height, serum creatinine, male gender,
positive serologic tests for hepatitis B or C, and a history of
diabetes or hypertension. After controlling for all of these
potential confounders, kidneys from CDCHR donors were
even less likely to be used for transplantation than those
from non-CDCHR donors (odds ratio 0.67, 95% CI 0.61–
0.74, p < 0.001). In sensitivity analysis, after adjusting for
OTPD the odds ratio for CDCHR status remained signifi-
cant at 0.75 (95% CI 0.65–0.86, p < 0.001), suggesting
the absence of substantial unmeasured confounders. Uti-
lization rates of CDCHR kidneys did not change over time
despite implementation of the OPTN policy in December
2007 mandating recipient notification (data not shown).
This regression model had an area under the receiver-
operating characteristic curve (AUROC) of 0.84, indicating
excellent performance for predicting utilization. Based on
this model, the predicted utilization rate for all non-ECD
kidneys during this time period would increase by 0.37%
if the CDCHR label did NOT exist. This suggests that 165
kidneys from January 2005 to February 2009, or approxi-
mately 41 kidneys per year are potentially being wasted as
a result of the CDC-high risk appellation.
Although CDCHR kidneys appear to be turned down more
often than non-CDCHR ones, receiving a CDCHR kidney
does not appear to negatively affect survival. At a median
follow-up time of 731 days, patients who received a CD-
CHR kidney had similar survival to those who received a
non-CDCHR kidney, as shown in Figure 1. Despite con-
trolling for multiple potential confounders using Cox re-
gression, receiving a kidney with CDCHR status was not
Table 3: Logistic regression of kidney transplantation for non-ECD
deceased donors
Variable (donor Odds
characteristics) ratio 95% C.I. p-Value
CDC high risk 0.67 0.61–0.74 <0.001
Donation after cardiac death 0.52 0.47–0.57 <0.001
Age (ref = 35–49)
0–10 2.14 1.67–2.74 <0.001
11–17 2.19 1.86–2.58 <0.001
18–34 1.57 1.44–1.71 <0.001
50–64 0.62 0.56–0.67 <0.001
65+ 1
Race (ref = Caucasian)
Black 1.03 0.94–1.12 0.531
Hispanic/Latino 1.31 1.19–1.44 <0.001
Non-Caucasian other 1.56 1.29–1.90 <0.001
Cause of death (ref = head trauma)
Anoxia 0.87 0.80–0.94 0.001
Cerebrovascular accident 0.73 0.67–0.79 <0.001
Other 0.50 0.43–0.57 <0.001
Height (per 10 cm) 1.04 1.45–1.54 <0.001
Serum Creatinine 0.40 0.39–0.42 <0.001
Male 0.87 0.81–0.93 <0.001
Blood type O 1.06 1.00–1.13 0.058
HBV positive 0.59 0.52–0.67 <0.001
HCV positive 0.11 0.10–0.12 <0.001
History of hypertension 0.53 0.49–0.57 <0.001
History of diabetes 0.46 0.42–0.52 <0.001
CI, confidence interval.
1Dropped from model due to colinearity.
associated with worse posttransplant survival (hazard ratio
1.06, 95% CI 0.89–1.26, p = 0.54).
Discussion
This study has demonstrated that kidney allografts bearing
a CDCHR label are approximately one-third less likely to
be used for transplantation than would otherwise be the
case if this label did not exist. Furthermore, we demon-
strate that CDCHR donor status has no significant impact
on median 2-year recipient posttransplant survival. This
lack of impact on short-term posttransplant survival was
also demonstrated in a recent study by Reese et al. (10).
Therefore, we estimate that approximately 41 otherwise
standard kidneys per year are potentially being wasted due
to being labeled as ‘high risk’.
Despite the reassuring survival outcomes for these organs
as a group, we do not propose that stratification of donors
by disease transmission risk or recipient notification should
be abandoned. Instead, updated criteria need to be devel-
oped which reflect the continuous nature of transmission
risk. A continuous measure may be more accurate in pre-
dicting risk associated with individual organs, and could
also help avoid the psychological bias associated with a di-
chotomous ‘high risk’ label (11). Additionally, although we
had hypothesized that underutilization of CDCHR organs
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Figure 1: Survival curves for kid-
ney transplant patients receiving or-
gans from CDC high risk donors
versus non-CDC high risk donors.
Includes only recipients of standard cri-
teria donor (SCD) kidneys.
would be caused in part by recipient notification require-
ments, we found no change in utilization of these organs
after implementation of the OPTN recipient notification pol-
icy in December 2007. This could be due to the limited time
since implementation of the policy, or it could suggest that
utilization of CDCHR organs depends mainly upon the indi-
vidual physicians and/or transplant centers rather than the
recipient. Indeed, an earlier study demonstrated that cen-
ters with formal protocols and procedures for consenting
recipients actually have higher utilization rates of CDCHR
organs (2). Therefore, utilization of these organs may de-
pend not so much on whether recipients are notified but
rather how this notification is done. We propose that stan-
dardized mechanisms need to be developed for educating
patients about the risks associated with all organs, not just
those designated as CDCHR. These methods should build
upon work which has demonstrated that risk communica-
tion is best done (1) using graphs, (2) using absolute rather
than relative risks and (3) providing contextual information
to account for innumeracy (12–14). Such methods could
then be applied to all risks associated with transplanta-
tion of any solid organ. Finally, standardized protocols may
also reduce fear of litigation, another potential reason for
underutilization of CDCHR kidneys. Such fear is indeed jus-
tifiable, since a recent case of HIV transmission has gen-
erated lawsuits alleging failure to adequately inform the
candidate of this potential risk (6).
The primary limitation of this study is the observational
nature. While the results demonstrate a strong associa-
tion between the CDCHR label and lower kidney utilization
rates, we cannot be certain the relationship was causal. Fur-
thermore, this data cannot determine whether decreased
utilization of CDCHR kidneys is occurring due to turn-down
by the physician or patient. This limitation is particularly
important because it will be difficult to fix the problem
without understanding its root location. Another limitation
is the duration of the follow-up time in our survival analysis.
While the median follow-up time is approximately 2 years,
we were limited by when the CDCHR status started to be
consistently recorded in the SRTR data set. Ideally, our sur-
vival analysis would examine a longer posttransplant time
scale. Finally, we were unable to measure actual rates of
disease transmission. At present the only mechanism for
measuring transmission rates relies on voluntary report-
ing by transplant centers, and is not reported in the SRTR
database (3).
In conclusion, we found that the label ‘CDCHR’ is indepen-
dently associated with lower utilization of deceased donor
kidneys. Yet these kidneys on average tend to have char-
acteristics associated with favorable graft function, and in-
dividuals that do receive CDCHR kidney transplants do not
experience worse posttransplant survival at 2 years. These
findings suggest that a dichotomous label is inadequate for
expressing risk of disease transmission, and may actually
be causing harm. Future research should focus on devel-
oping continuous models to predict disease transmission
risk associated with individual organs, and on formalizing
mechanisms for recipient education and notification about
organ-specific risks.
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